Shymkent

Researchers are evaluating the safety and effectiveness of three different doses of MORF-057 in adults with moderately to severely active Crohn's disease (CD). This Phase 2 study is randomized, double-blind, placebo-controlled, and conducted at multiple centers. It aims to compare MORF-057 to placebo to see how well it works in reducing disease activity and symptoms in this patient population. Participants will first go through a 14-week induction period where they receive one of three doses of MORF-057 or a matching placebo, all given orally. After this, all participants will enter a 38-week maintenance phase where they receive open-label MORF-057. Those who complete these 52 weeks of treatment may continue in a 52-week long-term extension to further monitor treatment effects and safety. Throughout the study, participants will have evaluations to assess their response to treatment using endoscopic scoring at Week 14. Researchers will monitor safety, symptom changes, and disease activity over the full treatment and extension periods. Study visits will include assessments, questionnaires, and clinical monitoring to track participants' health and treatment adherence over time.

Researchers are evaluating the clinical effectiveness of Ustekinumab in patients with Crohn's Disease through an observational study that includes both retrospective and prospective components. The study aims to assess the reduction in disease activity with a focus on the Crohn's Disease Activity Index over 24 weeks of therapy. The study involves patients who have been prescribed Ustekinumab for the first time between January 1 and December 31, 2024. Participants receive the usual care with Ustekinumab as prescribed, and the study observes their response to treatment without additional experimental interventions. Participants will be monitored for changes in their disease activity using the Crohn's Disease Activity Index at week 24. The study also involves collection of clinical data, monitoring for safety, and evaluating adherence to treatment. The total duration and detailed follow-up procedures are based on observing the patients through their routine care during the study period.

Researchers are evaluating the effects of adding Anifrolumab to the usual treatment for Systemic Lupus Erythematosus (SLE) in a real-world setting. This international study, called INTERSTELLAR, aims to provide important evidence on how Anifrolumab helps patients with SLE, including those with skin symptoms related to the disease. The study uses standardized criteria and measures across multiple countries such as Qatar, Saudi Arabia, Mexico, Costa Rica, Panama, Dominican Republic, Colombia, Argentina, Taiwan, and Egypt to allow comparisons between different populations. INTERSTELLAR is a multi-country, single-arm observational study that includes both retrospective data from the year before starting Anifrolumab and prospective follow-up for one year after treatment begins. Patients join the study when they receive their first prescription and infusion of Anifrolumab, following the approved country-specific guidelines. The study will collect data until the patient dies, stops participating, or the study ends. Clinical assessments and patient-reported outcomes related to lupus activity, skin involvement, fatigue, and quality of life will be gathered throughout the study. Participants will be assessed at various times including before treatment and at 1, 3, 6, and 12 months after starting Anifrolumab. Researchers will monitor lupus disease activity, skin symptoms, fatigue, and quality of life using standardized tools. Data will continue to be collected even if patients stop the treatment, as long as they agree to stay in the study. This approach helps provide a comprehensive understanding of Anifrolumab's impact in routine clinical practice over a full year.

This research aims to describe the rate of chronic kidney disease (CKD) diagnosis in patients with arterial hypertension (high blood pressure) and markers of CKD in Kazakhstan. The study is a multicenter, non-interventional, prospective observational study that also includes retrospective analysis. It focuses on patients with hypertension and markers such as albuminuria or reduced kidney filtration rate (GFR below 60 ml/min/1.73 m2). Participants are adults diagnosed with hypertension according to clinical guidelines, with specific laboratory markers of CKD measured within the last 12 months and persisting for at least 3 months. The study does not involve any interventions or treatments and observes patients' existing conditions and therapies. It evaluates the proportion of patients with CKD markers among those with hypertension and further assesses demographic and clinical characteristics as well as routine therapies before and after CKD diagnosis. During the study, researchers will collect data on patient medical records, laboratory test results, and diagnoses. The primary outcome is the proportion of patients with CKD markers within 16 months. Secondary outcomes include further evaluation of patients with confirmed CKD diagnoses. The study spans prospective observation and retrospective review, focusing on real-world clinical information without altering patient care.